General Information of Drug Combination (ID: DCID2PB)

Drug Combination Name
Fluocinolone Acetonide Ruxolitinib
Indication
Disease Entry Status REF
Hodgkin lymphoma Investigative [1]
Component Drugs Fluocinolone Acetonide   DMG2KI4 Ruxolitinib   DM7Q98D
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: L-1236
Zero Interaction Potency (ZIP) Score: 41.999
Bliss Independence Score: 42.679
Loewe Additivity Score: 10.544
LHighest Single Agent (HSA) Score: 11.07

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Fluocinolone Acetonide
Disease Entry ICD 11 Status REF
Choroiditis N.A. Approved [2]
Exanthem N.A. Approved [2]
Granuloma annulare N.A. Approved [2]
Inflammation 1A00-CA43.1 Approved [3]
Melasma ED60.1 Approved [2]
Pityriasis simplex N.A. Approved [2]
Primary cutaneous T-cell lymphoma N.A. Approved [2]
Fluocinolone Acetonide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Modulator [10]
------------------------------------------------------------------------------------
Fluocinolone Acetonide Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [11]
------------------------------------------------------------------------------------
Indication(s) of Ruxolitinib
Disease Entry ICD 11 Status REF
Essential thrombocythemia 3B63.1Z Approved [4]
High-risk myelofibrosis 2A20.2 Approved [5]
Myelofibrosis 2A22 Approved [6]
Myeloproliferative neoplasm 2A20 Approved [7]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [8]
Pancreatic cancer 2C10 Phase 3 [5]
Atopic dermatitis EA80 Phase 1/2 [9]
Vitiligo ED63.0 Phase 1/2 [9]
Ruxolitinib Interacts with 5 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Janus kinase 2 (JAK-2) TTRMX3V JAK2_HUMAN Modulator [12]
Janus kinase 1 (JAK-1) TT6DM01 JAK1_HUMAN Modulator [12]
Urokinase plasminogen activator surface receptor (PLAUR) TTPRL03 UPAR_HUMAN Inhibitor [13]
HUMAN janus kinase 1 (JAK-1) TTWKB01 JAK1_HUMAN Inhibitor [14]
HUMAN janus kinase 2 (JAK-2) TT0F5HE JAK2_HUMAN Inhibitor [14]
------------------------------------------------------------------------------------
Ruxolitinib Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Mitogen-activated protein kinase 14 (MAPK14) OT5TCO3O MK14_HUMAN Increases ADR [15]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Fluocinolone acetonide FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7077).
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5688).
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
7 Ruxolitinib FDA Label
8 Incyte begins Phase III trial of ruxolitinib to treat Covid-19. 20.April.2020.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
11 Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89.
12 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
13 Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.Cell Cycle. 2014;13(12):1958-69.
14 The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19): The Perspectives of Clinical Immunologists From China. Clin Immunol. 2020 May;214:108393.
15 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.